Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.
Our study aimed to find more effective protective agents against mucosa toxicity induced by methotrexate and 5-fluorouracil. We focused on the relationship between oral mucositis and keratinocyte injury and examined methotrexate and 5-fluorouracil-induced cytotoxicity in normal human epidermal keratinocyte cell lines. Cell viability and superoxide radical activity were measured based on converting WST-1 (4-[3-(4-indophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzen disulfonate) to a water-soluble formazan dye. DNA synthesis by 5-bromo-2'-deoxyuridine incorporation was measured as an indirect parameter of cell proliferation. Allopurinol and amifostine were used as the radical scavengers. l-glutamine was used as a mucosa-protective agent. A cyclooxygenase inhibitor interrupting the production of hydroxyl radicals in the arachidonic acid cascade was also examined. 5-fluorouracil and methotrexate caused cytotoxicity due to the activation of intracellular superoxide radicals specifically on normal human epidermal keratinocytes. From the electron spin resonance study, it was found that allopurinol was a superoxide radical scavenger, while amifostine was hydroxyl radical scavenger. Allopurinol showed no effect on the cytotoxicity due to 5-fluorouracil and methotrexate. The cell injury induced by methotrexate was restored by amifostine. However, the cell injury induced by 5-fluorouracil was markedly recovered by a selective cyclooxygenase-1 inhibitor compared to amifostine. It was suggested that amifostine and cyclooxygenase-1 inhibitor could be useful protective agents against methotrexate and 5-fluorouracil chemotherapeutic toxicity. Additionally, this in vitro cell injury model using normal human epidermal keratinocytes may be useful for understanding the pathophysiology of oral mucositis induced by chemotherapeutic agents.
Maiguma
Takayoshi
T
Department of Clinical Pharmacy, School of Pharmacy, Shujitsu University, Okayama, Japan.
Kaji
Hiroaki
H
Makino
Kazutaka
K
Teshima
Daisuke
D
D000493:Allopurinol / Q000378:metabolism; D004999:Amifostine / Q000494:pharmacology*; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity*; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004347:Drug Interactions; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005472:Fluorouracil / Q000633:toxicity*; D016166:Free Radical Scavengers / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008727:Methotrexate / Q000633:toxicity*; D010513:Periodontal Ligament / Q000166:cytology / Q000187:drug effects; D020011:Protective Agents / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D013280:Stomatitis / Q000139:chemically induced / Q000517:prevention & control
D000964:Antimetabolites, Antineoplastic; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D016166:Free Radical Scavengers; D020011:Protective Agents; D011720:Pyrazoles; D017382:Reactive Oxygen Species; C115461:SC 560; D005973:Glutamine; D000493:Allopurinol; D004999:Amifostine; D002118:Calcium; D005472:Fluorouracil; D008727:Methotrexate